Aadi Bioscience Stock (NASDAQ:AADI)
Previous Close
$2.21
52W Range
$1.21 - $5.70
50D Avg
$1.99
200D Avg
$1.84
Market Cap
$54.72M
Avg Vol (3M)
$225.98K
Beta
0.37
Div Yield
-
AADI Company Profile
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
AADI Performance
Peer Comparison
| Ticker | Company |
|---|---|
| GRCL | Gracell Biotechnologies Inc. |
| ANAB | AnaptysBio, Inc. |
| ARVN | Arvinas, Inc. |
| RVMD | Revolution Medicines, Inc. Warrant |
| MLYS | Mineralys Therapeutics, Inc. |
| AVTE | Aerovate Therapeutics, Inc. |
| ACRV | Acrivon Therapeutics, Inc. Common Stock |
| ERAS | Erasca, Inc. |
| ANTX | AN2 Therapeutics, Inc. |
| CRNX | Crinetics Pharmaceuticals, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| DSGN | Design Therapeutics, Inc. |
| RZLT | Rezolute, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| ADAG | Adagene Inc. |
| KURA | Kura Oncology, Inc. |
| RARE | Ultragenyx Pharmaceutical Inc. |